New study aims to block hepatitis b transmission from mother to baby

NCT ID NCT07542951

ENROLLING_BY_INVITATION Disease control Sponsor: The Third Affiliated Hospital of Guangzhou Medical University Source: ClinicalTrials.gov ↗

First seen May 01, 2026 · Last updated May 25, 2026 · Updated 3 times

Summary

This study tests two antiviral drugs, TAF and TDF, in pregnant women with chronic hepatitis B to see which is safer and more effective at preventing the virus from passing to their babies. About 200 women in early to mid-pregnancy will take one of the drugs daily until delivery. Researchers will monitor the babies for infections and birth defects, and track any side effects in the mothers.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEPATITIS B VIRUS INFECTION; PREGNANT WOMEN are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Locations

Department of Infectious Diseases, Guangdong Provincial Key Laboratory of Major Obstetric Diseases; Guangdong Provincial Clinical Research Center for Obstetrics and Gynecology, The Third Affiliated Hospital, Guangzhou Medical University,

Guangzhou, Guangdong, 450000, China

Conditions

Explore the condition pages connected to this study.

HEPATITIS B VIRUS INFECTION; PREGNANT WOMEN